Likang Takes AI Neoantigen Cancer Vaccine LK101 to Abu Dhabi Summit
Beijing – October 13, 2026 -- Likang Life Sciences, whose lead cancer vaccine candidate LK101 holds clinical trial authorization from China's NMPA (2023) and U.S. FDA IND clearance (2025), will sponsor and exhibit at the Abu Dhabi Future Health Summit 2026 on October 20–22 at the ADNEC Centre.
Likang co-founder joins October 21 oncology panel
Shannon Cheung, Co-Founder and Vice Chairman of Likang, will speak on the panel "The Future of Cancer" on October 21. The session will cover precision oncology and the translation of innovative cancer treatments into clinical practice. It forms part of the summit's Abu Dhabi Blueprints series and will examine the roles of research, investment, policy, and international collaboration in getting new therapies to patients.